Bristol Myers Squibb stock holds steady after Q2 2026 growth and guidance
Published on 08/29/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb Inc. (ISIN US0897961004) stock was last quoted in the mid-$60 range with a regular-session close of $66.58 on August 28, 2026, according to recent New York Stock Exchange market data as of 4:00 p.m. ET, leaving the shares slightly above one cited fair-value estimate of $62.96. This latest price level comes in the wake of Q2 2026 results that showed solid revenue growth and a stronger earnings profile, supported by the company’s newer therapies.
Q2 2026 revenue and earnings picture
Recent coverage of Bristol Myers Squibb’s most recent quarter indicates that in Q2 2026 the company generated revenue of $12.97 billion, representing 6 percent year-over-year growth, or 5 percent growth when adjusted for foreign exchange effects. The same Q2 2026 summary notes that non-GAAP earnings per share reached $2.04 versus $1.46 in Q2 2025, while GAAP EPS rose to $1.62, showing that earnings grew faster than revenue as margins benefited from mix and cost discipline. Within that revenue mix, the company’s growth portfolio delivered $7.6 billion in sales in Q2 2026, which is a 15 percent increase compared with the prior-year quarter and highlights how newer products are expanding more quickly than the overall business.
In contrast, the legacy portfolio generated $5.4 billion in revenue in Q2 2026, down 4 percent year-over-year as older medicines faced ongoing generic and biosimilar competition. The quantified comparison between the 15 percent growth in newer therapies and the 4 percent decline in legacy products underscores a clear shift in Bristol Myers Squibb’s revenue base toward higher-growth assets. For investors, the fact that earnings per share expanded from $1.46 to $2.04 on a non-GAAP basis in one year, while overall revenue increased by 6 percent, suggests that the company’s operating leverage and portfolio transition are supporting profitability.
Stock valuation and market context
Based on the most recent quote snapshot for Bristol Myers Squibb on the New York Stock Exchange as of August 28, 2026 at 4:00 p.m. ET, the stock closed at $66.58 with a modest 0.55 percent decline on the day and then ticked slightly higher to $66.60 in after-hours trading. At $66.58, the shares stand above a referenced fair-value estimate of $62.96, indicating that the market is assigning a premium versus that valuation benchmark, supported by the 15 percent growth in the company’s newer product portfolio and the strong earnings trend.
That same overview points out that the growth portfolio’s $7.6 billion in Q2 2026 revenue compares with the total $12.97 billion revenue base, meaning newer therapies accounted for a significant share of the quarter’s sales. The 6 percent year-over-year revenue increase and the acceleration in earnings per share from $1.46 to $2.04 on a non-GAAP basis give Bristol Myers Squibb room to continue investing in its pipeline while still returning cash to shareholders through dividends and potential share repurchases. The relatively small 0.55 percent decline in the latest regular session suggests that the market is digesting the quarter’s details without a sharp repricing, even as investors weigh valuation against growth and competition.
Representative product and pipeline focus
One representative example of the business model behind Bristol Myers Squibb’s numbers is its focus on innovative therapies in areas such as oncology, hematology, cardiovascular disease, and immunology. The company’s newer products, which make up the growth portfolio referenced in the Q2 2026 summary, are designed to address high unmet medical needs and support long-term revenue expansion. The 15 percent increase in sales from these newer therapies in Q2 2026 compared with the prior-year quarter shows how the company’s pipeline investments are converting into commercial performance, helping offset the 4 percent revenue decline in legacy medicines.
Shares hold in the mid-$60 range
As of August 28, 2026 at 4:00 p.m. ET, Bristol Myers Squibb stock closed at $66.58 on the New York Stock Exchange in USD, with a slight move to $66.60 in after-hours trading that kept the shares in the mid-$60 range. This price level, combined with Q2 2026 revenue of $12.97 billion, 6 percent year-over-year growth, and non-GAAP earnings per share of $2.04 versus $1.46 a year earlier, frames how the market is currently valuing the company’s transition toward higher-growth therapies and its evolving earnings profile.
Company fact box
Company: Bristol Myers Squibb Inc.
ISIN: US0897961004
Ticker: BMY
Exchange: New York Stock Exchange
Price (as of August 28, 2026, 4:00 p.m. ET): $66.58 USD
Sector / Industry: Health care / Pharmaceuticals and biotechnology
